Kane Biotech revives commercial activity for revyve gel

Executive Summary

• Kane Biotech Inc. is resuming commercial activities for its revyve antimicrobial wound gel and spray product lines in both the United States and Canada, marking a strategic restart of its commercial operations.
• The company has appointed two new Vice Presidents of Business Development to lead expansion efforts: Sherida (Kay) Watkins Weaver for the U.S. market and Patti Burke-Martin for the Canadian market.
• Commercial activities are supported by new non-exclusive distribution agreements in the U.S. and a converted agreement in Canada, following regulatory clearance from the FDA (510(k)) and Health Canada.

Key Details

• Product Regulatory Status: revyve antimicrobial wound gel and revyve antimicrobial wound gel spray have received 510(k) clearance from the U.S. Food and Drug Administration and approval from Health Canada.
• U.S. Commercial Strategy: Kane signed non-exclusive distribution/sales agreements with Medstream Healthcare Solutions, LLC (Dorval, Fla.) and Patient Care Medical (Austin, Tex.). Initial shipments are expected in the near term.
• Canada Commercial Strategy: Kane converted its existing distribution agreement with Best Buy Medical Canada to a non-exclusive arrangement and initiated targeted sales and sampling initiatives.
• Management Appointments:
  • Sherida (Kay) Watkins Weaver: Appointed Vice President of Business Development, United States. She brings over 20 years of experience in wound care commercialization, including leadership roles at Omeza and Relevate Health, with expertise in market access, reimbursement, and adoption strategies.
  • Patti Burke-Martin: Appointed Vice President of Business Development, Canada. She is a national wound care leader with senior roles at EO2 Concepts, Coloplast, and ConvaTec, with a record of building high-performing teams and driving technology adoption.
• Sales Context: While current sales in both countries are not yet material, the company describes this as a "meaningful restart" of its commercial engine.

Notable Quotes

• "We are executing on our commitment to reset Kane Biotech using a disciplined market approach. We will continue to generate scientific credibility, clinical validation and with that, the commercial infrastructure." — Dr. Robert Huizinga, Interim Chief Executive Officer
• "Kay and Patti bring deep expertise and trusted relationships in their respective markets. Their leadership will be instrumental as we expand our distribution network and support the growing adoption of revyve." — Dr. Robert Huizinga, Interim Chief Executive Officer